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Isoprenylation is Necessary for the Full Invasive Potential
of RhoA Overexpression in Human Melanoma Cells
Eric A. Collisson, Dafnis C. Carranza, Ingrid Y. Chen, and Michael S. Kolodney
Department of Medicine, Division of Dermatology, UCLA School of Medicine, Los Angeles, CA, U.S.A.
Rho GTPases are signaling molecules known to control
cell motility. Several recent studies have suggested a
role for Rho proteins in mediating tumor metastasis
independent of their a¡ects on cell proliferation. As
Rho proteins require post-translational modi¢cation
with a geranlygeranyl moiety for full activity, we tested
the a¡ect of blocking geranylation on localization,
downstream signaling, and stimulation of invasion.
Expression of a constitutively active Rho construct
in A375 melanoma cells dramatically stimulated
invasion through Matrigel membranes; however, a
constitutively active RhoA mutated so that it cannot
be geranylated, failed to stimulate invasion. Moreover,
expression of epitope or GFP tagged modi¢cations
of this nongeranylatable constitutively active Rho
demonstrated that geranylation is necessary for correct
cellular localization of Rho. Geranylation was also
found to be necessary for full downstream activation
of serum response factor mediated transcription.
Pharmacologic inhibition of Rho geranylation pro-
duced similar inhibition of Rho localization, signaling,
and invasion. Our results suggest that inhibition of
Rho geranylation may be an attractive pharmacologic
target for inhibiting melanoma metastasis. Key words:
metastatis/statins/isoprenylation/RhoA. J Invest Dermatol
119:1172 ^1176, 2002
T
he lethality of melanoma is due to its high meta-
static potential rather than local tumor invasion. As
therapy provides little bene¢t after metastasis
has occurred (Rigel et al, 1996) anti-metastatic
chemoprevention strategies may reduce mortality
in melanoma prone individuals by delaying or preventing metas-
tasis of the primary neoplasm. Evidence from epidemiologic stu-
dies and animal models ( Jani et al, 1993) suggests that the statin
class of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhi-
bitors inhibit melanoma progression and metastasis. Statins are
known to inhibit the post-translational lipidation of Rho
GTPases, a family of proteins that have recently been implicated
in causing melanoma metastasis (Clark et al, 2000). In order to in-
vestigate the potential role of Rho signaling in mediating the anti-
metastatic e¡ects of statins, we have examined the signi¢cance of
blocking Rho lipidation in modulating melanoma cell invasion.
The 3-hydroxy-3-methylglutaryl coenzyme A reductase cho-
lesterol biosynthetic pathway has numerous e¡ects on cellular
metabolism. In addition to producing cholesterol, mevalonate
metabolism also supplies lipids required for protein isoprenyla-
tion. The mevalonate pathway produces farnesyl pyrophosphate
and geranylgeranyl pyrophosphate, which in turn post-transla-
tionally modify the carboxy termini of many signaling mole-
cules, such as the Ras superfamily of small GTPases (Laufs and
Liao, 2000). Farnesylation of Ras proteins, which has been exten-
sively studied, facilitates their appropriate localization to cellular
membranes, where interaction with other signaling molecules al-
lows these GTPases to participate in mitogenic signal transduc-
tion (Bar-Sagi and Hall, 2000). In contrast to Ras, most Rho
GTPases control cell motility and adhesion rather than mitogen-
esis and are geranylgeranylated rather than farnesylated (Adamson
et al, 1992).
Indirect lines of evidence suggest that, analogous to farnesyla-
tion of Ras, geranylgeranylation of Rho is essential for full acti-
vation of their downstream e¡ectors. Rho function can be
inhibited by statins, which deplete the cell of the geranylgeranyl
pyrophosphate intermediate (Kranenburg et al, 1997) or by gera-
nylgeranyl transferase inhibitors (GGTI), which block the enzyme
responsible for attachment of the geranylgeranyl moiety to the
carboxy terminus of Rho (Lesh et al, 2001). These drugs likely
a¡ect Rho signaling by abrogating its ability to interact with up-
stream and downstream components of various signal transduc-
tion cascades.
Both statins and GGTI have been shown to prevent growth of
tumor cells in vivo (Sun et al, 1998; Kusama et al, 2002). These
results suggest that pharmacologically inhibiting Rho geranyl-
geranlyation is responsible for the prevention of metastasis
observed; however, these drugs theoretically target all post-trans-
lationally geranylgeranylated proteins in addition to Rho, and
formal demonstration that prevention of Rho geranylation is spe-
ci¢cally responsible for the e¡ects of these inhibitors on tumor
metastasis has been lacking to date.
In this study, we evaluated the e¡ect of Rho isoprenylation on
its ability to promote invasiveness. As the isoprenylation status
and downstream e¡ectors of RhoA have been the best studied
of the Rho family, we concentrated our experimental e¡orts on
this protein.We used both pharmacologic and genetic approaches
to block geranylation of RhoA.We then examined the cellular
distribution of RhoA after treatment with statins or mutation
of a residue critical for the geranylgeranyl post-translational mod-
i¢cation of RhoA.We then compared the e¡ects of both statin
treatment and RhoA mutation of geranylgeranyl acceptor
residues on the in vitro invasiveness of human melanoma cells.
Our results highlight the importance of Rho isoprenylation in
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melanoma invasiveness and suggest that pharmacologic inhibi-
tion of this post-translational modi¢cation is an attractive target
for the prevention of melanoma metastasis.
MATERIALS AND METHODS
Cell lines and chemicals Madin^Darby canine kidney (MDCK) cells
were purchased from ATCC (Manassas, VA), 293T cells were a gift from
Dr Charles L. Sawyers (UCLA School of Medicine). A375 cells
expressing the murine ecotropic receptor were from Dr R. Hynes (MIT,
Somerville, MA), and have been described previously (Clark et al, 2000).
All cells were maintained in Dulbecco’s minimal Eagle’s medium with
10% fetal bovine serum and penicillin/streptomycin (Invitrogen,
Carlsbad, CA) in a 7.5% CO2 incubator.
Atorvastatin (P¢zer, Groton, CT, USA) 20mg tablets were dissolved in
methanol, binders removed by centrifugation and used at 4 mm unless
otherwise indicated. The geranylgeranyl transferase inhibitor GGTI-298 or
farnesyl transferase inhibitor (FTI)-277 (both from Calbiochem, San
Diego, CA) were dissolved in dimethyl sulfoxide and used at 10 mm.
Plasmids, transfections, and retroviruses V5 epitope tagged V5-
G14V RhoAwt and V5-G14V RhoAdt were engineered by polymerase
chain reaction based cloning. The template myc-G14V RhoAwas a gift of
Dr Alan Hall (University College, London), and is de¢cient in GTPase
activity, rendering it constitutively active. The forward primer AAGCG-
GCCGCGCACCATGGGTAAGCCTATCCCTAACCCTCTCCTCGGT-
CTCGATTCTACGTGCCATCCGGAAG) and the reverse primers (AAG-
CGGCCGCTTTCACAAGACAAGGCACCC) (V5-G14V) or (AAGCG-
GCCGCTTTCACAAGACAAGGCGCCCAGATTTTT) (V5-G14V) were
used to generate E600 bp fragments, which were then gel isolated, using
the Qiagen gel puri¢cation system (Qiagen, Valencia, CA), digested with
Not1 (New England Biolabs, Beverly, MA) and ligated into the Not1 site of
pMSCV iresGFP, a kind gift of Dr Janusz Kabarowski (UCLA, Los
Angeles, CA) (Kabarowski et al, 2000).
High-titer retroviral stocks were produced by transfecting each of the
pMSCV retroviral constructs into 293T cells, by the calcium phosphate
coprecipitation method, together with  ecotropic packaging vector pSV-
-E-MLV, which provides ecotropic packaging helper function as well as
the ecotropic envelope in trans. Replication de¢cient retrovirus-containing
culture supernatants were collected from 48 to 72 h post-transfection, at 6 h
intervals, and pooled together.
Filtered viral supernatants were added to A375-P cells in the presence of
polybrene (Sigma, St Louis, MO) three times, at 4 h intervals, to achieve a
higher overall rate of infection. Cells were then replenished with regular
culture medium. Four days postinfection, the cells were sorted for GFP
expression by a FACSvantage cell sorter (Becton Dickinson, Franklin
Lakes, NJ).
N-terminal GFP fusion construct pEGFP-G14V RhoAwt was a
gift from Dr David Michaelson (NYU, New York, NY). G14V RhoAdt
was engineered by polymerase chain reaction based cloning. The forward
primer (AAGCTTGCTGCCATCCGGAAG) and the reverse primer
(GAATTCTTTCACAAGACAAGGCGCCCAGATTTTT) (GFP-G14V
RhoAdt) were used to generate a E600 bp fragment, which was then gel
isolated, using the Qiagen gel puri¢cation system (Qiagen), digested with
EcoR1 and HindIII (New England Biolabs) and then ligated into the
pEGFP C3 plasmid (Clontech, La Jolla, CA) in frame with the N-
terminal EGFP molecule encoded by this plasmid. All constructs were
veri¢ed by sequencing.
Live cell imaging MDCK cells were plated on to 3 cm dishes
with built-in coverslips (MatTek, Ashland, MA) at 90% con£uency and
then transfected with pEGFP-G14V RhoA plasmids 24 h later using
Lipofectamine 2000s exactly as recommended by the manufacturer
(Invitrogen) for MDCK cells. Atorvastatin or ethanol were added at the
time of transfection. Thirty-six hours after transfection cells were imaged
live on a 510 laser scanning confocal microscope (100 PlanApo 1.4 NA
objective; Zeiss, Jena, Germany). Digital images were processed with
Adobe Photoshops v5.0.
Western blot analysis V5-G14V-RhoAwt and V5-G14V-RhoAdt
protein expression was assessed by western blot analysis of cell lysates.
Brie£y, cells were washed twice with cold phosphate-bu¡ered saline
(PBS), pelleted, and resuspended in lysis bu¡er (50mM Tris pH 8,
150mM NaCl, 1% Triton X-100, 10 mg of aprotinin per ml, 0.5mM
phenylmethylsulfonyl £uoride, 2 mg of leupeptin per ml, 2 mg of pepstatin
per ml) for 30min on ice. Cell lysates were then clari¢ed by micro-
centrifugation at 8000 g for 10min at 41C. The protein concentrations
were determined with Advantage protein determination dye (Cyto-
skeleton, Denver, CO) by absorbance at 590 nm. Cellular proteins
(50mg) were separated by sodium dodecyl sulfate^polyacrylamide gel
electrophoresis 12% polyacrylamide and transferred on to nitrocellulose
membranes.
The membranes were blocked with PBST (PBSþ 0.1% Tween 20)
containing 5% milk and immunoblotted for protein expression by
incubation with anti-V5 (Invitrogen) or anti-RhoA (Cytoskeleton)
antibody at a 1 : 3000 dilution in PBST^5% milk for 1h at room
temperature. The blots were washed three times for 20min with PBST at
room temperature, exposed to horseradish peroxidase-conjugated sheep
anti-mouse immunoglobulin G (Promega, Madison, WI) at a 1 : 5000
dilution for 1h at room temperature, and washed with PBST three times
for 20min at room temperature. Protein expression was visualized with
enhanced chemiluminescence detection reagents (Amersham, Piscataway,
NJ) and by exposure to X-ray ¢lm (Kodak, Rochester, NY).
Cell fractionation V5-G14V RhoAwt/dt protein levels were assessed in
cytosolic and membranous pools prepared by fractionation of cellular
lysates as described previously (Shimizu et al, 1997). Brie£y, cells were
transfected with the indicated expression construct using the calcium
phosphate method. Twenty-four hours later drugs were added as
described above, and incubated for 24 h. At this time cells were washed
twice with cold PBS and collected in physiologic bu¡er 10mM Tris pH
7.4, 140mM NaCl, 5mM ethylenediamine tetraacetic acid, 2mM
dithiothreitol, 1mM phenylmethylsulfonyl £uoride, 1 mg of aprotinin per
ml, 2 mg of leupeptin per ml, and 2 mg of pepstatin per ml (500 ml per
100mm con£uent dish). The cells were homogenized in physiologic
bu¡er by repeated passage through a 21-gauge hypodermic needle, and
the lysate was centrifuged with a microcentrifuge for 10min at 500 g at
41C to clear insoluble debris. Membranous and cytosolic material was
obtained by ultracentrifugation at 14,000 (20,000 g) r.p.m. for 30min at
41C. The supernatant was designated the cytosolic fraction, and the pellets
were resuspended in physiologic bu¡er containing 0.1% sodium dodecyl
sulfate (100ml per 30mm con£uent dish) and designated the membranous
fraction. V5-G14V RhoA was analyzed by electrophoretic separation of
cytosolic and membranous protein pools on sodium dodecyl sulfate^12%
polyacrylamide gels followed by western blotting analyses with an anti-V5
monoclonal antibody as described above. Film was scanned by a
phosphoimager (Molecular Dynamics, Sunnyvale, CA). The total area
under the curve in the cytosolic plus the membranous fraction was used
as the denominator, and each fraction’s relative protein amount was
calculated as a percentage of this total.
Serum response factor (SRF) luciferase assays 293T cells at 50%
con£uence in 24 well plates were cotransfected with 0.1 mg of the reporter
plasmid pSRF-¢re£y luciferase (Stratagene, La Jolla, CA), 0.1mg of pCMV
LacZ, and 0.1 mg of pMSCV G14V RhoAwt or pMSCV G14V RhoAdt or
pMSCV GFP (totaling 0.3 mg DNA) by the calcium phosphate
coprecipitation system (Stratagene). Twenty-four hours later, cells were
lyzed in 200ml of cell lysis bu¡er (Promega). Luciferase values were
obtained by analyzing 10 ml of lysate according to the standard protocol
provided in the Luciferase Assay Kit (Promega) in a Lumat LB 9501
luminometer for 20 s. b-galactosidase activity was determined by the
OPNG method. Relative luciferase activity is represented as ¢re£y
luciferase value/b-galactosidase value.
Invasion assays A375 cells were plated in rehydrated Matrigel (Becton
Dickinson) chambers at a density of 5104 per chamber with 0% serum
in the top well and 5% serum in the bottom chamber with Atorvastatin
added to both the top and bottom chambers as indicated or an equal
volume of ethanol was added as a control. After 48 h, invaded cells were
counted and the number of invaded cells was expressed in graphic form,
with standard deviation from the mean of the three trials expressed as
error bars. Each statin dosage was examined in triplicate wells, and
all experiments were duplicated. Invasion assays with G14VRhoAwt,
G14VRhoAdt, and GFP expressing A375 cell lines were conducted
identically, with the exception of Atorvastatin. In parallel experiments, the
e¡ect of Atorvastatin on A375 cell viability was ascertained by use of
an ethidium calcein/homodimer cytotoxicity assay (Molecular Probes,
Eugene, OR) exactly as recommended by the manufacturer.
RESULTS
Statins inhibit A375 invasion in vitro To evaluate the e¡ect of
atorvastatin on A375 cell invasion, we performed invasion studies
on parental A375 cells using the Matrigel invasion chamber
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system. As seen in Fig 1, atorvastatin potently inhibited the
invasion of A375 cells at a concentration that did not cause
appreciable cell death.
Isoprenylation status and subcellular localization of
RhoA We hypothesized that geranylgeranylation was essential
for the correct subcellular distribution of RhoA. To evaluate the
role of the geranylgeranyl modi¢cation of RhoA in cells, we
generated V5 epitope tagged G14V (constitutively active) RhoA
mutants. V5-G14V RhoAwt contains the wild-type CAAX box
(CLVL), whereas V5-G14V RhoAdt has the C-terminal cystine
mutated to an arginine (RLVL), and is thus unable to accept an
isoprenoid modi¢cation.
We next tested if our V5 tagged constructs localized pro-
perly. These constructs were transiently expressed in 293T cells
treated with vehicle (Con), FTI or GGTI. The amount of tagged
protein in membrane and soluble fractions was quanti¢ed by
western blotting, scanned, digitally quanti¢ed, and presented
in graphic form. Figure 2(A) demonstrates that activated
G14V RhoAwt is predominantly in the cell membrane but
is released into the cytoplasm in GGTI or statin treated cells,
and is una¡ected by a speci¢c FTI (FTI-277). As expected
isoprenylation-de¢cient Rho is recovered exclusively in the
soluble cell fraction.
To visualize geranylgeranyl modi¢ed RhoA in living cells,
we generated GFP fusions of the aforementioned G14V
(constitutively active) RhoA mutants. GFP-G14V RhoAwt
contains the wild-type CAAX box (CLVL), whereas GFP-G14V
RhoAdt has the C-terminal cystine mutated to an arginine
(RLVL), and is thus unable to accept an isoprenoid
modi¢cation. These constructs were expressed in MDCK cells
chosen for their semicolumnar morphology allowing clear
membrane visualization. As seen in Fig 2(C), a substantial
portion of GFP-G14V RhoAwt is localized in the membrane
compartment. Figure 2(D,E) demonstrates the exclusion of
Figure1. Statins inhibit A375 invasion. A375 melanoma cells were incu-
bated with the indicated concentrations of atorvastatin for 48 hours and
assayed for invasion in Matrigel chambers. Error bars are7 one SD.
Figure 2. Cellular Localization of RhoA mutants. In Fig 2A, 293Tcells were transiently transfected with the indicated expression constructs and 24 hours
later treated with EtOH (Con), Farnesyltrasferase inhibitor (FTI), geranylgeranyltransferase inhibitor (GGTI) or Atorvastatin (Statin) for 24 hours. At this
point cells were fractionated into soluble and membranous pools as described in Materials and Methods. Soluble (Sol) and membranous (Mem) fractions
were immunoblotted with an anti V5 antibody. In Fig 2B blots were scanned and quanti¢ed as described in Materials and Methods. In Fig 2C, D, and E,
pEGFP-G14VrhoAwt (C and D) or pEGFP-G14Vdt (E) constructs were transfected into MDCK cells as described. Atorvastatin was added to D at 4 uM at
the time of transfection. Images of live cells were obtained as described in Materials and Methods.
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RhoA from the plasma membrane with either statin treatment of
GFP-G14V RhoAwt (Fig 2D) or mutation of the terminal
cystine (Fig 2E). Of note, either statin treatment or ablation
of the isoprenoid acceptor residue excluded activated RhoA
from both the plasma membrane and the interior Golgi and
endoplasmic reticular membranes. In contrast, the prenylatable
GTP bound RhoA is enriched in these compartments as
evidenced by the positively (GFP-G14V RhoAwt) or negatively
(GFP-G14V RhoAwt plus statin or GFP-G14V RhoAdt) imaged
membranous organelles.
Isoprenylation is necessary for full transcriptional response
to Rho signaling As most cellular signaling is initiated at the
membrane, we hypothesized that RhoA isoprenylation is
necessary for full activation of its downstream e¡ectors. To test
this premise, we examined the ability of the aforementioned
constructs to activate a known Rho-responsive transcriptional
promoter, SRF. As seen in Fig 3, the G14V RhoAwt construct
with the wild-type CAAX box strongly enhanced transcription
of a SRF driven luciferase reporter construct, whereas G14V
RhoAdt did so only weakly, indicating the necessity of an intact
prenylation acceptor cysteine for complete activation of down-
stream Rho e¡ectors.
Isoprenylation is necessary for Rho-Augmented invasive
potential Given the signaling de¢cit observed in ungerayla-
table forms of RhoA we hypothesized that an ungeraylatable
RhoA would be unable to promote invasion to the extent
geranylgernylated RhoA does in A375 cells. To this end, we
generated recombinant retroviruses containing V5 epitope
tagged G14V (constitutively active) RhoA mutants with
(V5-G14V RhoAwt) or without (V5-G14V RhoAdt) the
C-terminal isoprenoid acceptor cystine, along with an IRES
GFP sequence. Viruses were pseudotyped with the MMLV
envelope and used to infect dividing A375-P cells expressing
the ecotropic receptor. Infected cells were selected for GFP
expression by FACS. After sorted cells were expanded, greater
than 99% remained GFP positive by £ow cytometry, indicating
that the mRNA containing both the RhoA constructs and GFP
was e¡ectively expressed (data not shown). As seen in Fig 4,
expression of V5-G14V RhoAwt increased the rate of invasion
of A375 cells almost 4 -fold. In striking contrast, the iso-
prenylation de¢cient mutant V5-G14V RhoAdt was unable to
augment the invasiveness of A375 cells to a statistically
signi¢cant degree.
DISCUSSION
A number of studies have highlighted the importance of Rho
GTPases in cell motility, migration, and cancer metastasis. It is
well known that these proteins are post-translationally modi¢ed
by geranylgeranyl moieties; however, the function this modi¢ca-
tion plays in cells remains unclear. Although a number of studies
have shown that the oncogenic properties of the closely related
ras proteins depend on their farnesylation state, little is known
about the function of Rho prenylation. Here, we show that a
constitutively active form of RhoA profoundly augments the in-
vasion of a human melanoma cell line in vitro. Furthermore, by
using carboxy terminal mutants of RhoA, we demonstrate that
prenylation of RhoA is essential to its localization to cell mem-
branes, activation of downstream e¡ectors, and promotion of cell
invasion.
The carboxyl-terminal amino acid sequence of small GTPases,
the CAAX box, appears to contain all the critical determinants
for the speci¢city of their interaction with prenyl-transferases.
Adamson et al (1992) showed that only the cysteine within the
CAAX box is important for the correct intracellular localization
of RhoA protein. Thus, to create a prenylation de¢cient constitu-
tively GTP bound RhoA construct, we mutated the cysteine es-
sential for prenyl conjugation in the CAAX box of G14V RhoA.
Prenylatable G14V RhoAwith the wild-type CAAX box (G14V
RhoAwt) localized to both the membrane and cytoplasmic com-
partments of 293 and A375 cells expressing this protein. Of note,
RhoA was not exclusively associated with plasma membranes as
was observed in NE-115 neuronal cells (Kranenburg et al, 1997) or
endothelial cells (Lesh et al, 2001). This is likely due to a combina-
tion of factors, including cell type speci¢c handling of RhoA as
well as relative expression levels achieved in each experiment. As
reported previously (Allal et al, 2000), GGTI and statins abrogated
this membrane association, whereas FTI did not alter localization.
These ¢ndings con¢rm that the recombinant RhoA used in this
study is geranylgeranylated. Furthermore, the CAAX to RAAX
mutation (G14V RhoAdt) completely abolished membrane asso-
ciation.We obtained similar results in live cell microscopy experi-
ments with MDCK cells transfected with GFP tagged versions of
the wild-type and CAAX-RAAX mutated versions of G14V
RhoA. The perinuclear pattern of £uorescence suggested that ac-
tivated RhoA might accumulate in intracellular membranes as
well as the plasma membrane as described previously (Strassheim
et al, 2000). These results raise the possibility that these endocellu-
lar organelles may well represent a nidus of Rho signaling. The
experiments here described, however, did not directly address this
Figure 3. G14V RhoAdt fails to activate SRF. 293T cells were transiently
transfected with the indicated expression constructs with a SRF reporter.
Values were normalized to Beta-Gal for transfection e⁄ciency. Error bars
are7 one SD.
Figure 4. G14V RhoAdt fails to promote invasion. A375 cells expressing
the indicated constructs were plated in Matrigel invasion chambers in tri-
plicate. After 48 hours invaded cells were counted in each well. Error bars
are7 one SD.
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possibility. Importantly, we also noted that treatment with a sta-
tin was su⁄cient to redistribute membrane-associated RhoA
to the cytoplasm thereby assuming a cellular distribution indis-
tinguishable from the G14V-RhoAdt RAAX mutant. Taken
together, our ¢ndings underscore the essential nature of
the CAAX isoprenyl modi¢cation of RhoA for membrane
localization.
The previous observation of Clark et al (2000) that overexpres-
sion of RhoC augmented metastasis of a human melanoma cell
line both in vivo and in vitro, suggested to us that Rho’s metastasis
promoting activity might be dependent on its isoprenylation sta-
tus. As RhoA has been found to be purely geranylgeranylated and
no such information exists for RhoC, we chose to focus our ef-
forts on RhoA isoprenylation.To this end, we generated cell lines
expressing G14V RhoAwt and G14V RhoAdt from the identical
parental strain of A375 human melanoma cells as in Clark et al,
and assayed ability to transverse a Matrigel invasion chamber.
A375 cells expressing G14V RhoAwt were dramatically more in-
vasive than GFP expressing controls. As predicted, expression of
G14V RhoAdt failed to augment the invasive ability of A375
cells. These experiments demonstrate that G14V RhoA overex-
pression confers an invasive phenotype to human melanoma cells
and that its potential to do so is dependent on geranylgeranyl
modi¢cation.
These studies extend the growing body of literature suggesting
a role for the Rho family of proteins in the invasion and metas-
tasis of tumor cells. Overexpression of RhoA and RhoC have
been shown to correlate with a poorer prognosis in colorectal
(Yoshioka et al, 1999) and breast (Fritz et al, 1999) carcinoma.
Furthermore, a large randomized clinical trial recently found that
statins may prevent mortality due to malignancy (Pedersen et al,
2000) Taken together these studies suggest that the isoprenylation
step of Rho activation plays a crucial part in the in vivo promo-
tion of metastasis.
The work described herein represents, to our knowledge,
the ¢rst formal demonstration that isoprenylation de¢cient
Rho proteins are incapable of promoting invasion of human
cancer cells. Rho overexpression in human cancers likely initiates
remodeling of the actin cytoskeleton through its downstream
e¡ectors ROCK and mDia. This reorganization in turn
alters the tumor cell’s a⁄nity for neighboring cells through integ-
rin and cadherin based adhesions.We show herein that abrogation
of the isoprenylation step of RhoA a¡ects its localization to
cellular membranes. This disruption of Rho localization
may modulate its interaction with upstream and downstream
signaling components, thereby attenuating Rho’s ability to
promote invasion. Although further in vivo work is required,
our data strongly suggest that therapeutic strategies targeting
Rho isoprenylation have the potential to inhibit tumor cell
metastasis.
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